Ottawa, April 28, 2022 – Innovative Medicines Canada (IMC), the association representing Canada’s research-based pharmaceutical sector, issued the following statement in response to the Ontario budget released by Finance Minister Peter Bethlenfalvy today.
“Innovative Medicines Canada welcomes the release of Ontario’s 2022 budget and the government’s ongoing commitment to the life sciences sector, including an investment of $15 million in a new Life Sciences Innovation Program and a commitment to continue working with key stakeholders to ensure the people of Ontario have access to medications and treatments when they need them,” said Pamela Fralick, President of IMC. “Now, more than ever, access to life-saving medicines and vaccines, a strong healthcare system, and a robust life sciences sector are essential.”
IMC looks forward to working with the Ontario government to continue to strengthen and grow Ontario’s life sciences ecosystem.
About Innovative Medicines Canada
Innovative Medicines Canada is the national association representing the voice of Canada’s innovative pharmaceutical industry. The association advocates for policies that enable the discovery, development, and delivery of innovative medicines and vaccines to improve the lives of all Canadians and supports the members’ commitment to being a valued partner in the Canadian healthcare system. The association represents 49 companies who invest nearly $1.4 billion in R&D annually, fueling Canada’s knowledge-based economy, while contributing $8 billion to Canada’s economy. Guided by the Code of Ethical Practices, all members work with governments, private payers, healthcare professionals, and stakeholders in a highly ethical manner.
